This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Intuitive Surgical, Inc. (ISRG) Just Reclaimed the 50-Day Moving Average
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?
Intuitive Surgical (ISRG) Q2 Earnings Beat, Procedures Robust
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results reflect a healthy demand for procedures. Higher pricing boosts procedure sales. An improvement in margins buoys well.
5 Non-Tech Nasdaq Stocks to Buy Amid Index's Recent Bloodbath
by Nalak Das
We have narrowed our search to five Nasdaq Composite-listed non-tech stocks. These are: COST, ISRG, IBKR, TXRH, FSLR.
Markets Book Profits; Netflix, Intuitive Beat Estimates in Q2
by Mark Vickery
Year-to-date, the Nasdaq is still +20%, the S&P +16%, the Russell +9% and the Dow +7.5%.
Compared to Estimates, Intuitive Surgical (ISRG) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Intuitive Surgical (ISRG) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Intuitive Surgical, Inc. (ISRG) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Intuitive Surgical (ISRG) delivered earnings and revenue surprises of 16.34% and 2.02%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Reasons to Add Masimo (MASI) Stock to Your Portfolio Now
by Zacks Equity Research
Masimo's (MASI) R&D activities raise optimism about the stock.
Intuitive Surgical (ISRG) Gains 26% Year to Date: Here's Why
by Zacks Equity Research
Investors are optimistic about Intuitive Surgical's (ISRG) strength in robotics.
Is Intuitive Surgical (ISRG) a "Buy" Ahead of Q2 Earnings Announcement?
by Bryan Hayes
The established medical company has surpassed the earnings mark in each of the last four quarters.
McKesson (MCK) Gains 26% Year to Date: What's Backing the Rally?
by Zacks Equity Research
McKesson's (MCK) shares have risen 1.5% year to date on the back of solid fundamentals. Increasing volumes of prescription and specialty drugs boost the top line.
Masimo (MASI) Sues Politan for Misstatements, Delays Annual Meet
by Zacks Equity Research
Masimo (MASI) sues Politan to correct material misstatements in an ongoing proxy battle, rescheduling its annual meeting. Politan denies allegations and vows to prevent any further delay, criticizing Masimo's tactics.
How to Play Intuitive Surgical (ISRG) Ahead of Q2 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) second-quarter results are likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs might have hurt margins.
The Zacks Analyst Blog DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific
by Zacks Equity Research
DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific are included in this Analyst Blog.
3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio Now
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for Inogen (INGN) stock.
Buy 5 Medical Devices Stocks to Enhance Your Portfolio in 2H
by Nalak Das
We have narrowed our search to five Medical Instruments stocks. These are: DXCM, TMO, ISRG, ALC, HOLX.
3 Reasons Why You Should Hold McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson's (MCK) robust Biologics business raises optimism about the stock.
Here's Why You Should Add DaVita (DVA) to Your Portfolio
by Zacks Equity Research
DaVita's (DVA) strength in its kidney care raises optimism about the stock.
Reasons to Add Intuitive Surgical (ISRG) to Your Portfolio Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to raise optimism among investors owing to its strength in robotics.
Intuitive Surgical, Inc. (ISRG) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) closed the most recent trading day at $442.30, moving -0.5% from the previous trading session.
Investing Lessons: The 10 Best Stocks of the Past 20 Years
by Andrew Rocco
The 10 best performing stocks over the past two decades share several similar attributes. Investors should study and understand the common traits of true market leaders.
Intuitive Surgical (ISRG) Rises 10% in a Month: What's Next?
by Indrajit Bandyopadhyay
Intuitive Surgical (ISRG) is making strides in the robotic-assisted surgery market with its existing and new launches. However, macro challenges are likely to continue to hurt its performance.
Intuitive Surgical, Inc. (ISRG) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
The latest trading day saw Intuitive Surgical, Inc. (ISRG) settling at $442.56, representing a +0.06% change from its previous close.
Intuitive Surgical (ISRG) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Intuitive Surgical's (ISRG) strength in robotics.
Wall Street Bulls Look Optimistic About Intuitive Surgical (ISRG): Should You Buy?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Intuitive Surgical (ISRG) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Intuitive Surgical, Inc. (ISRG) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Intuitive Surgical (ISRG) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.